 |
|
Oral Anticoagulation Treatment in the Elderly
A Nested, Prospective, Case-Control Study
Gualtiero Palareti, MD;
Jack Hirsh, MD;
Cristina Legnani, PhD;
Cesare Manotti, MD;
Armando D'Angelo, MD;
Vittorio Pengo, MD;
Marco Moia, MD;
Giuliana Guazzaloca, MD;
Serena Musolesi, PhD;
Sergio Coccheri, MD
Arch Intern Med. 2000;160:470-478.
Background Whether elderly patients are at increased risk of complications during oral anticoagulant treatment (OAT) is still a matter of debate.
Method Bleeding and thrombotic events occurring during OAT in 461 patients, aged 75 years or older when they started OAT, and in 461 patients younger than 70 years, matched for sex, OAT indication, and treating center, were examined in a prospective, multicenter, inception-cohort study.
Results Bleeding rate was 9.9% and 6.6% patient-years in elderly and young patients, respectively (P = .07), and 2.1% and 1.1% for major bleeding (P = .19); 6 and 1 events, respectively, were fatal (all intracranial, relative risk, 6.4; P = .05). In the elderly, bleeding rate was lower (4.5%) for international normalized ratios (INRs) between 2.0 and 2.9; it was higher during the first 90 treatment days (P = .05) and when arterial vascular disease was the indication for OAT (P = .03). Thrombosis rate was 4.2% and 2.5% patient-years in elderly and young patients, respectively (P = .10); however, 13 and 5 events were fatal (relative risk, 2.8; P = .04). Thrombosis rate was lower (1.5%) for INRs between 2.0 and 2.9; it was higher during the first 90 treatment days (P<.001) and 6 of 7 venous events occurred at lower than 2.0 INRs.
Conclusions A nonsignificant trend was noted toward a higher rate of both bleeding and thrombotic complications in elderly vs matched younger patients. Intracranial bleeding and fatal thrombotic events were significantly more frequent in the elderly. Our results also indicate that lower than 2.0 INRs do not preclude bleeding in the elderly nor offer adequate protection from thrombotic events. Moderate anticoagulation (2.0-3.0 INRs) in elderly patients seems the safest and most effective.
From the Departments of Angiology and Blood Coagulation, University Hospital S Orsola-Malpighi, Bologna, Italy (Coordinating Center) (Drs Palareti, Guazzaloca, Legnani, and Coccheri); Research Centre, Hamilton Civic Hospitals, McMaster University, Hamilton, Ontario (Dr Hirsh); Centro Emostasi, Ospedale Regionale, Parma (Dr Manotti), Ambulatorio Emostasi Trombosi, IRCCS Ospedale S Raffaele, Milano (Dr D'Angelo), Servizio Prevenzione Trombosi, Cattedra di Cardiologia, Università di Padova, Padova (Dr Pengo), Centro Emofilia e Trombosi A. Bianchi Bonomi, IRCCS Ospedale Maggiore, Università di Milano, Milano (Dr Moia); and Istituto di Statistica, Università di Bologna, Bologna (Dr Musolesi), Italy.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT
| FULL TEXT
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation
Morrison et al.
Age Ageing 2007;36:117-119.
FULL TEXT
Risks of Oral Anticoagulant Therapy With Increasing Age
Torn et al.
Arch Intern Med 2005;165:1527-1532.
ABSTRACT
| FULL TEXT
Clinical Experience: Management of Oral Anticoagulant in Clinical Practice: A Retrospective Study of 187 Patients
Mahe et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:1339-1342.
ABSTRACT
| FULL TEXT
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation
Fang et al.
ANN INTERN MED 2004;141:745-752.
ABSTRACT
| FULL TEXT
Safety of Anticoagulation Therapy in Well-informed Older Patients
Kagansky et al.
Arch Intern Med 2004;164:2044-2050.
ABSTRACT
| FULL TEXT
The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT
| FULL TEXT
Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation
Wehinger et al.
Stroke 2001;32:2246-2252.
ABSTRACT
| FULL TEXT
Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin
Hylek et al.
ANN INTERN MED 2001;135:393-400.
ABSTRACT
| FULL TEXT
|
